Cognitive disorders represent a colossal public health challenge globally. Recent comprehensive epidemiological data from the Global Burden of Disease (GBD) 2021 study provide crucial insights into the evolving landscape of neurodegenerative conditions. Specifically, the global Alzheimer's disease burden demonstrates intricate epidemiological shifts between 1990 and 2021 across various socio-demographic spectrums. While global prevalence continues to rise steadily, significant inequalities exist in mortality and disability-adjusted life-years (DALYs) between high-middle and low-middle sociodemographic index (SDI) nations. Furthermore, the analysis identifies metabolic dysfunction, particularly elevated fasting plasma glucose, as the leading modifiable contributor to dementia-related disability. Understanding these intricate patterns is critical for clinicians and healthcare policymakers worldwide.

Global Trends in the Alzheimer's Disease Burden

Between 1990 and 2021, the global age-standardized prevalence of Alzheimer's disease and related dementias expanded from 672 to 694 per 100,000 population. This reflects an average annual percentage change (AAPC) of 0.09%, demonstrating a gradual yet persistent escalation in overall disease prevalence. In contrast, the global age-standardized mortality rate remained essentially flat over this three-decade span, displaying an AAPC of 0.00%. Concurrently, age-standardized DALYs exhibited a modest increase from 446 to 451 per 100,000 population, corresponding to an AAPC of 0.01%.

These epidemiological metrics underscore an important clinical reality. Although advancements in supportive care and chronic disease management have stabilized age-standardized mortality rates, overall life expectancy has lengthened. Consequently, populations live longer with chronic cognitive impairment. This prolonged survival with functional disability creates substantial cumulative pressure on families, healthcare delivery systems, and community resources. Additionally, the data highlight that demographic aging is expanding the absolute volume of affected individuals. Therefore, health systems must adapt swiftly to accommodate this sustained rise in neurocognitive morbidity.

Diverging Regional Disparities Across Sociodemographic Strata

The epidemiological trajectory of cognitive disorders demonstrates striking geographic and socio-demographic variations. For instance, the highest age-standardized prevalence remains concentrated in populations aged 65 to 69 years within high-middle SDI territories, particularly East Asia, including China. Conversely, an alarming paradox emerges when examining mortality and disease disability. Populations aged 65 to 69 years residing in low-middle SDI regions, such as South Asia and India, experience the highest mortality and DALY rates.

This pronounced inequality reflects fundamental differences in healthcare infrastructure, access to diagnostic services, and long-term supportive management. In high-middle SDI countries, earlier diagnostic detection and structured geriatric programs help maintain lower case-fatality rates. In sharp contrast, low-middle SDI nations frequently face significant diagnostic delays, limited access to specialized neurological care, and fewer community-based support structures. Consequently, patients in these developing regions often present at advanced disease stages. As a result, individuals in lower-resource settings suffer disproportionately higher rates of premature mortality and catastrophic disability, requiring urgent regional health interventions.

High Fasting Plasma Glucose as the Foremost Modifiable Contributor

A crucial takeaway from the GBD 2021 analysis is the identification of high fasting plasma glucose as the top-ranking risk factor for dementia-related DALYs from 1990 to 2021. The metabolic epidemic, characterized by rising rates of impaired fasting glucose, prediabetes, and type 2 diabetes mellitus, directly compounds neurodegenerative vulnerability.

Epidemiological evidence increasingly shows that chronic dysglycemia accelerates the onset and progression of cognitive decline. Moreover, South Asian populations carry an exceptionally high susceptibility to early-onset metabolic derangements and vascular dysfunction. Consequently, the convergence of increasing diabetes prevalence and population aging creates a compounding risk for dementia in this region. Identifying elevated fasting glucose as the primary driver of disability highlights a tangible opportunity for targeted prevention. By prioritizing strict glycemic control and metabolic stabilization across adult populations, clinicians can potentially avert a substantial proportion of future dementia cases. Therefore, comprehensive risk mitigation must place metabolic health at the core of dementia prevention strategies.

Pathophysiological Links Between Hyperglycemia and Neurodegeneration

The biological pathways linking impaired glucose regulation to neurodegeneration involve several interconnected mechanisms. Chronic hyperglycemia promotes peripheral and central insulin resistance, which severely impairs cerebral energy metabolism. Because the brain relies heavily on glucose utilization for synaptic plasticity and neuronal maintenance, impaired insulin signaling directly compromises cognitive function.

Additionally, persistent hyperglycemia induces non-enzymatic glycation, leading to the accumulation of advanced glycation end-products. These molecules bind to specific receptors, triggering chronic neuroinflammation, reactive oxygen species generation, and microvascular endothelial damage. Furthermore, cerebral microvascular dysfunction compromises the blood-brain barrier integrity, exacerbating ischemic injury and white matter hyperintensities. Concurrently, insulin resistance impairs the clearance of toxic neuroproteins, particularly amyloid-beta and hyperphosphorylated tau, accelerating classical Alzheimer neuropathology. Thus, metabolic dysregulation and vascular pathology act synergistically to drive cognitive decline. Recognizing these cellular pathways allows physicians to view glycemic control not merely as an endocrine target, but as a vital neuroprotective imperative.

Clinical Implications for Healthcare Systems in Developing Regions

The findings of this GBD study present profound clinical and structural implications for low- and middle-income countries. Given that South Asian populations face the highest burden of dementia mortality and DALYs, local healthcare systems require immediate restructuring. Primary care physicians must serve as the first line of defense in identifying early cognitive impairment.

Currently, neurocognitive assessments remain underutilized in routine clinical practice across developing regions. To mitigate this deficit, primary care settings should integrate routine cognitive screening tools for older adults, particularly those with comorbid diabetes or hypertension. Furthermore, establishing multidisciplinary care teams that combine primary physicians, neurologists, endocrinologists, and geriatric nurses is crucial for holistic management. Such integrated care models can optimize secondary prevention, delay institutionalization, and reduce caregiver burnout. In addition, strengthening public health campaigns to raise awareness about dementia symptoms can diminish persistent societal stigma. Ultimately, bridging diagnostic and therapeutic gaps in these regions will reduce preventable disability and improve quality of life.

Strategic Approaches: Integrating Metabolic and Cognitive Health

Effectively curbing the rising dementia trajectory requires proactive, population-wide preventive strategies. Because high fasting plasma glucose represents the leading modifiable driver of DALYs, routine metabolic screening must be coupled with early neuroprotective counseling. Lifestyle interventions, including Mediterranean or DASH diets, structured aerobic exercise, and weight optimization, yield dual benefits for metabolic stability and brain health.

From a pharmacotherapeutic perspective, clinicians should prioritize antidiabetic agents that exhibit proven neuroprotective and cardiovascular benefits. Emerging evidence suggests that GLP-1 receptor agonists and SGLT2 inhibitors may reduce neuroinflammation and enhance cerebral vascular integrity, offering promising therapeutic avenues. Additionally, aggressive management of concurrent cardiovascular risks, such as hypertension and dyslipidemia, further protects cerebral microcirculation. Public health policies must support these clinical efforts by subsidizing screening and expanding access to essential medications. Through synergistic clinical care, lifestyle modification, and health policy reform, healthcare systems can alleviate the global burden of neurodegenerative disease.

What did the GBD 2021 study reveal about global dementia prevalence?

The GBD 2021 analysis demonstrated that the global age-standardized prevalence of Alzheimer's disease and other dementias increased from 672 to 694 per 100,000 population between 1990 and 2021. Meanwhile, age-standardized mortality remained unchanged, and disability-adjusted life-years slightly rose, reflecting prolonged survival with chronic cognitive impairment worldwide.

Why do dementia mortality and DALY rates differ across sociodemographic regions?

Diverging rates stem from disparities in healthcare infrastructure and resource access. While high-middle SDI countries show high prevalence due to increased screening and longevity, low-middle SDI regions like South Asia suffer higher mortality and DALY rates due to diagnostic delays, limited specialist access, and inadequate long-term community support.

How does elevated fasting plasma glucose increase the risk of dementia?

High fasting plasma glucose induces chronic cerebral insulin resistance, neuroinflammation, oxidative stress, and microvascular endothelial damage. These pathological processes impair cerebral glucose metabolism, compromise blood-brain barrier integrity, and reduce amyloid-beta clearance, accelerating both vascular brain injury and neurodegenerative pathology characteristic of Alzheimer's disease and related dementias.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Healthcare professionals should utilize their clinical judgment and consult relevant clinical guidelines when evaluating and treating patients. Refer to the latest local and national guidelines for clinical practice.

References

1. Wang R Global Burden of Alzheimer's Disease and Other Dementias during 1990-2021: A Global Burden of Disease and Risk Factors Study 2021-Based Study. Neuroepidemiology. 2026. doi: 10.1159/000543578. PMID: 39837288.


2. GBD 2021 Dementia Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2022;7(2):e105-e125.


3. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and approach to treatment. Nat Rev Endocrinol. 2018;14(10):591-604.